Literature DB >> 10736082

Tropisetron plus dexamethasone is more effective than tropisetron alone for the prevention of postoperative nausea and vomiting in children undergoing tonsillectomy.

R Holt1, P Rask, K P Coulthard, M Sinclair, G Roberts, J Van Der Walt, V MacKenzie, M Rasmussen.   

Abstract

The 5-HT3 antagonists are effective in reducing postoperative nausea and vomiting (PONV) associated with paediatric tonsillectomy. Although prophylactic tropisetron can reduce the incidence of PONV by half, the resulting level of over 40% is still unacceptably high. The aim of this study was to evaluate the effect of adding dexamethasone to tropisetron. In a blinded study, 59 children (mean age 6.1 years) were administered 0.1 mg.kg-1 up to 2 mg of tropisetron and 66 children (mean age 5.7 years) received the same dose of tropisetron plus 0.5 mg.kg-1 up to 8 mg of dexamethasone. Both drugs were given intravenously during induction of anaesthesia for tonsillectomy. During the inpatient stay of 24 h, the incidence of postoperative vomiting in the tropisetron alone group was 53% compared with 26% in the combination group (P=0.002, chi-squared). A significant reduction in nausea from 53% to 30% was also observed (P=0.02). Parents completed a daily diary for 5 days following discharge. Delayed vomiting occurred in 27% and 11% of the tropisetron and combination therapy groups, respectively (P=0.025) Sixteen percent and 9%, respectively, required medical attention (P=0.27). Tropisetron plus dexamethasone is more effective than tropisetron alone in reducing the incidence of PONV following paediatric tonsillectomy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10736082     DOI: 10.1046/j.1460-9592.2000.00475.x

Source DB:  PubMed          Journal:  Paediatr Anaesth        ISSN: 1155-5645            Impact factor:   2.556


  15 in total

Review 1.  Steroids for improving recovery following tonsillectomy in children.

Authors:  David L Steward; Jedidiah Grisel; Jareen Meinzen-Derr
Journal:  Cochrane Database Syst Rev       Date:  2011-08-10

Review 2.  Update on the management of postoperative nausea and vomiting.

Authors:  Anthony L Kovac
Journal:  Drugs       Date:  2013-09       Impact factor: 9.546

3.  Penehyclidine enhances the efficacy of tropisetron in prevention of PONV following gynecological laparoscopic surgery.

Authors:  Zhiming Zhang; Yuehong Zhuang; Fang Ouyang; Ansheng Zhang; Bin Zeng; Miaoning Gu
Journal:  J Anesth       Date:  2012-08-10       Impact factor: 2.078

4.  [Intrathecal opioid medication for perioperative analgesia in severely handicapped children undergoing spinal operations].

Authors:  A Schmitz; B Salgo; M Weiss; C M Dillier; A Frotzler; A C Gerber
Journal:  Anaesthesist       Date:  2010-07       Impact factor: 1.041

Review 5.  RETRACTED ARTICLE: Combination Antiemetic Regimens for Prevention of Postoperative Nausea and Vomiting : Focus on High-Risk Patients.

Authors:  Yoshitaka Fujii
Journal:  Clin Drug Investig       Date:  2002-09       Impact factor: 2.859

Review 6.  Management of postoperative nausea and vomiting in children.

Authors:  Anthony L Kovac
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

Review 7.  Prevention of postoperative nausea and vomiting in children following adenotonsillectomy, using tropisetron with or without low-dose dexamethasone.

Authors:  Mirjam Liechti; Rita Feurer; Dominique Gross; Achim Schmitz; Katharina Stutz; Andreas Gerber; Markus Weiss
Journal:  J Anesth       Date:  2007-08-01       Impact factor: 2.078

Review 8.  Management of postoperative nausea and vomiting in children.

Authors:  Pasquale De Negri; Giorgio Ivani
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 9.  Acute gastroenteritis in children: role of anti-emetic medication for gastroenteritis-related vomiting.

Authors:  Alexander K C Leung; Wm Lane M Robson
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

Review 10.  Postoperative Nausea and Vomiting in Pediatric Patients.

Authors:  Anthony L Kovac
Journal:  Paediatr Drugs       Date:  2020-10-27       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.